Melanoma differentiation associated gene-7 (Mda-7)/IL-24 was previously cloned into ZD55 (an adenovirus with E1B55 deleted) to form ZD55-IL-24, which had much better antitumor effect than Ad-IL-24. According to its good antitumor properties, ZD55-IL-24 has been used in preclinical studies. But ZD55-IL-24 alone still could not completely eradicate established tumors in all nude mice. It was reported that IL-24 could induce and enhance the activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (a member of tumor necrosis factor (TNF) superfamily). Accordingly, the combined use of ZD55-IL-24 and ZD55-TRAIL was carried out in this study. Treatment with both ZD55-IL-24 and ZD55-TRAIL could induce more significant apoptosis in cancer cells in vitro compared with ZD55-IL-24 or ZD55-TRAIL alone. The combination of the two replicative adenoviruses had better antitumor activity in vivo than that of single oncolytic adenovirus and led to complete eradication of xenograft tumors in all treated mice. Upregulation of TRAIL was observed in tumor cells infected with ZD55-IL-24 and studies of the apoptotic cascade regulators indicate that ZD55-IL-24 could further enhance the activation of apoptosis through the TNF family of death receptors. We demonstrated for the first time the potential therapeutic effect of combined ZD55-IL-24 with ZD55-TRAIL for the targeted therapy of cancer.
Melanoma differentiation associated gene-7 (Mda-7) was identified among all the upregulated genes during terminal differentiation of human melanoma cells by substraction hybridization strategy. 1 Further biochemical studies revealed that mda-7 belongs to the interleukin 10 (IL-10)-related family of proteins and was named as IL-24. Earlier studies showed that expression of IL-24 by plasmid or replication-defective adenovirus that harbored IL-24 suppressed cell growth and induced apoptosis in a wide variety of cancer cell lines, including melanoma, breast, lung, cervix, colon and prostate carcinomas, but not normal cells. [2] [3] [4] [5] However, the mechanism by which IL-24 induces its selective apoptosis is complicated, depending on the cell type studied. Previous studies have demonstrated that IL-24 can induce apoptosis at multiple levels by activating caspase cascade and upregulating P53, Bax, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and growth arrest and DNA damage protein family genes. [6] [7] [8] Additional mechanisms for IL-24-mediated cell killing have revealed its regulation of inducible nitric oxide synthase and mitogen-activated protein kinase in melanoma and JUN kinase, b-catenin, phosphatidylinositol 3 0 -kinase and double-stranded RNA-dependent protein kinase in lung and breast tumor cells. [9] [10] [11] [12] [13] Thus, IL-24 exerts its tumor-suppressive effects via different signaling pathways in different tumor types. Besides the apoptosis induction by Ad-IL-24, additional antitumor properties including tumor cell invasion and metastasis, antiangiogenic effects and direct bystander cytotoxicity have also been identified. These results indicated that IL-24 was a novel and ideal tumor suppressor gene and could be potentially widely applicable for antitumor therapy.
The direct effect of IL-24 gene therapy on human tumor xenografts in nude mice is also demonstrated in breast and lung cancer cells. A phase I trial using intratumoral injections of Ad-IL-24 (INGN 241) was conducted in patients with refractory cancer. [14] [15] [16] As expected, INGN 241 can induce apoptosis in a large percentage of tumor volume via a single intratumoral injection. However, as the INGN 241 virus is nonreplicating, the clinically significant response can be seen only with repeat injection of INGN 241. 17 In our previous studies, the targeting oncolytic adenoviruses armed with therapeutic genes have been developed and this strategy for cancer therapy was called as targeting gene virotherapy of cancer. 18, 19 The targeting oncolytic adenovirus used in our studies was named as ZD55, in which the E1B 55-kDa gene was deleted and a clone site was added for easy insertion of foreign genes. The foreign gene IL-24 was cloned into ZD55 to form oncolytic adenovirus ZD55-IL-24. The effect of ZD55-IL-24 on growth suppression and apoptosis induction was found to be more significant than that of Ad-IL-24 in vitro. 20 Similarly, the animal tumor model studies also showed that antitumor efficacy of ZD55-IL-24 was much better than that of Ad-IL-24.
Although ZD55-IL-24 had good antitumor effect, the xenograft tumors could not be completely eliminated by oncolytic adenovirus ZD55-IL-24 alone. To strengthen the antitumor effect, the concept of targeting dual genevirotherapy strategy was devised, which uses a combination of two oncolytic adenoviral vectors carrying different therapeutic genes. TRAIL is a type II transmembrane protein related to tumor necrosis factor (TNF) family factors and considered as a promising anticancer agent. 21 Many studies have shown that both the membrane-bound and the soluble extracellular domain of TRAIL can induce apoptosis in a broad range of tumor cells without affecting most normal cells. 22, 23 Transgenic TRAIL expression delivered by adenovirus can induce apoptosis and apoptotic bystander effects in several human cancer cell lines in vitro 24 and in vivo xenograft models of human glioblastoma, breast, 25 prostate 26 and liver carcinoma. 27 Our previous studies suggested that antitumor activity could be enhanced by oncolytic adenovirus expressing TRAIL. Furthermore, combination treatment with TRAIL and chemotherapy can substantially enhance the cytotoxic effects of these agents, even in some resistant tumors. 28 It has also been demonstrated that there are higher levels of TRAIL and its receptor DR4 in Ad-IL-24-treated lung tumor cells than in cells treated with Ad-luc or phosphate-buffered saline (PBS). Many previous studies have suggested that combination of two therapeutic genes mediated by replication-defective vectors has exerted synergic or compensatory antitumor activity. 29, 30 Based on all available data, we decided to evaluate the combined use of ZD55-IL-24 and ZD55-TRAIL and the results are presented.
In this study, we used oncolytic adenovirus vectors expressing TRAIL or IL-24 to examine the effect of combination use on colorectal cancer cells in vitro and in vivo. The synergistic effect was observed in inhibition of tumor cell proliferation and eradication of tumor xenografts in nude mice. The molecular mechanism involved in the tumor growth suppression mediated by the interaction between IL-24 and TRAIL has also been discussed. Our data showed that the antitumor effect of the combined use of ZD55-IL-24 and ZD55-TRAIL is more evident than each adenovirus used alone and suggest novel promising strategy for cancer gene therapy.
Materials and methods
Cell lines and culture conditions HEK293 (embryonic kidney containing the E1A region of Ad5) was obtained from Microbix Biosystem Inc. (Toronto, Ontario, Canada). All cell lines, SW620, HCT116, HT29 (human colorectal carcinoma), Hep3B (human hepatocarcinoma), A549 (human lung carcinoma), NHLF (human normal lung fibroblast) and MRC5 (human normal embryonic lung cell line), were purchased from the American Type Culture Collection (Rockville, MD); HEK293, A549, Hep3B, MRC5, HCT116 and SW620 cell lines were cultured in Dulbecco's modified essential medium supplemented with 10% heatinactivated fetal bovine serum (FBS), 4 mM glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin. HT29 and NHLF cells were grown in RPMI 1640 medium containing 10% FBS.
Virus construction, plaque assays and virus infection protocol ZD55 was constructed in our lab. Oncolytic adenovirus ZD55 carrying enhanced green fluorescent protein (ZD55-EGFP), ZD55 carrying TRAIL (ZD55-TRAIL) and IL-24 (ZD55-IL-24) were constructed and described previously. 18 The viruses were plaque purified, propagated on HEK293 cells and purified by centrifugation banding on cesium chloride by standard procedures. Titers of adenoviruses were determined by plaque assay on HEK293 cells. Cells were infected with adenoviruses at different doses at 371C. Cell viability was evaluated by a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, St Louis, MO).
Western blot analysis
To determine the expression of various proteins, Western blot analysis was performed as described previously. Cells were harvested by trypsinization and resuspended in lysis buffer (62.5 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (SDS), 10 mM glycerol, 1.55% dithiothreitol (DTT)). The total protein concentration was determined by the Bio-Rad protocol. Then, protein samples were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Amersham). Membranes were blocked in 5% nonfat dry milk and incubated with primary antibodies, then detected by the appropriate secondary antibodies and revealed with an enhanced chemiluminescence system (Amersham life Sciences Inc., Arlington Heights, IL). The primary antibodies used were mouse Release of cytochrome c from mitochondria Untreated and virus-treated cells were harvested by centrifugation at 1000 g for 5 min at 41C. Cell pellets were washed once with ice-cold PBS and resuspended with five volumes of 20 mM HEPES-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycol tetraacetate, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride and 250 mM sucrose. Cells were homogenized and centrifuged at 750 g for 10 min at 41C. The supernatants were centrifuged at 100 000 g for 15 min at 41C and the obtained supernatants were used for identification of cytosolic cytochrome c by immunoblotting.
Cytotoxicity assay
Tumor cell lines (SW620, HCT116 and HT29) and normal cell line (NHLF) were infected with ZD55-EGFP, ZD55-IL-24, ZD55-TRAIL or their combination at various multiplicity of infections (MOIs), respectively. After 7 days, cells were exposed to 2% crystal violet in 20% methanol for 10 min and washed. The results were documented as photographs.
Cell viability assay
Cells were plated in 96-well plates and treated with various adenoviruses. At the indicated time, medium was removed, and fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 371C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. The absorbance from the plates was read on a Bio-Rad Microplate Reader Model 655 at 595 nm.
Flow cytometry
At specific time points, the cells were harvested via trypsinization, washed with PBS, fixed with 75% ethanol and stored at À201C. Cells were then centrifuged, washed with PBS and digested with 100 ml RNase A (0.5 g/l) at 371C for 30 min, and 400 ml propidium iodide solution (100 mg/ml propidium iodide, 1% Triton X-100, 150 mM NaCl) was added. After 30 min, the apoptosis ratio was analyzed and the sub-G0/G1 cellular DNA content measured using FACScan flow cytometer equipped with CELLQUEST and ModFIT LT for Mac V1.01 software (Becton-Dickinson, San Jose, CA). in size, mice were randomized into five groups and a daily dose of 5 Â 10 8 PFU of examined viruses suspended in 100 ml of PBS or 100 ml PBS alone was administrated intratumorally for 4 days. At the end of the experiments, the tumors were harvested for histopathological and TdTmediated dUTP-biotin nick end labeling (TUNEL) analysis.
Studies on xenograft tumors in nude mice

Immunohistochemical staining
Tumors were harvested and fixed in 4% paraformaldehyde, embedded in paraffin and cut in 4 mm sections. These sections were stained with monoclonal anti-IL-24 and anti-TRAIL antibodies at a 1:500 dilution. The slides were then washed with PBS and incubated with the avidin-biotin-peroxidase complex reagent (Vector Laboratories, Burlingame, CA) and detected with diaminobenzidine tetrahydrochloride (DAB) solution containing 0.006% hydrogen peroxide. Hematoxylin was used as a counterstain. Tissue sections stained without primary antibodies were used as negative controls.
TUNEL assay
To detect the apoptotic cells in tumor specimens, the In Situ Cell Apoptosis Detection Kit (Sino-American Biotechnology Company, Luoyang, China) was used. The tumor sections were deparaffinized in xylene and rehydrated through decreasing concentrations of ethanol. After incubation with 20 mg/ml proteinase K and 0.3% H 2 O 2 , the sections were washed with PBS and incubated with equilibration buffer. The Biotin-11-dUTP and TdT was added in a humidified chamber at 371C for 60 min and the cells were combined with avidin-horseradish peroxidase at 371C for 60 min, colorized with DAB. Hematoxylin was used as a counterstain.
Statistical analysis
The data reported in this paper represent the means of three independent experiments and the bars show the standard deviation. Student's t-test was used to calculate the statistical significance of the experimental results. The significant level was set at Po0.05.
Results
Combined use of ZD55-IL-24 and ZD55-TRAIL inhibits cell proliferation in vitro
The human IL-24 and TRAIL genes were cloned into the targeting oncolytic adenoviral vector ZD55 and were separately or in combination used in the treatment of human cancer cells in vitro. ZD55-EGFP was used as control. Several human colorectal cancer cell lines ZD55-IL-24 and ZD55-TRAIL gene therapy for cancer L Zhao et al (SW620, HT29 and HCT116) and a normal human lung fibroblast cell line (NHLF) were infected with ZD55-IL-24 and ZD55-TRAIL, separately or in combination. cytopathic effect (CPE) assay was performed in vitro and the results are shown in Figure 1a . For different cancer cell lines, the cytotoxic sensitivity seems different for ZD55-IL-24 or ZD55-TRAIL alone. However, the combination treatment with ZD55-IL-24 and ZD55-TRAIL exhibits synergistic antiproliferative effect in most of the cancer cell lines. But no inhibitory effect was observed in NHLF cells with any treatment (Figure 1a) .
The CPE of ZD55-EGFP, ZD55-IL-24, ZD55-TRAIL and their combination on studied cancer cell lines was also assessed by MTT assay (Figure 1b) . At the same MOI, daily analysis for cell viability demonstrated significant inhibition of cell proliferation in all cancer cell lines treated with different oncolytic adenovirus compared with cells treated with PBS. However, the inhibitory effect on tumor cell proliferation was greater and more pronounced in the cancer cells treated with ZD55-IL-24 and ZD55-TRAIL than with either one alone. Similar work was also carried out in other cancer cell lines including lung and liver carcinomas and the same antitumor effect was observed (data not shown). No inhibitory effect was detected in normal cells. The CPE was dosage-and time-dependent.
IL-24 overexpression induces TRAIL and DR4 expression
It was reported that IL-24 could induce the expression of TRAIL and DR4 in human lung cancer cells (A549). But no further evidence was available. In this study, the colorectal cancer cell line SW620 was infected with either ZD55-IL-24 alone or its combination with ZD55-TRAIL and compared to untreated control cells. The cells were harvested at various time points after infection and extracts were prepared for Western blot analysis (Figure 2a) . The expression of IL-24 could be detected only in tumor cells that were infected with ZD55-IL-24 or its combination use with ZD55-TRAIL. Interestingly, upregulation of TRAIL and DR4 was observed in tumor cells even after treatment with ZD55-IL-24 alone. Both IL-24 and TRAIL gene expression increased in a timedependent manner. These results demonstrate that ZD55-IL-24 can upregulate the expression of TRAIL and DR4 in human colorectal cancer cells (SW620).
Effects of combined use of ZD55-IL-24 and ZD55-TRAIL on apoptosis FACS analysis was performed to test the apoptosis induction by combined use of ZD55-IL-24 and ZD55-TRAIL in colorectal cancer cell line (SW620) and normal cell line (MRC5). Cells not infected with oncolytic adenovirus served as a negative control (Figure 2b ). For the combined treatment, the MOI ratio of ZD55-IL-24 to ZD55-TRAIL was 1:1. For the single treatment, the total viral particles added to the cells were similar to that of the combination treatment. The apoptotic effect of combined ZD55-IL-24 and ZD55-TRAIL was more significant than either ZD55-IL-24 or ZD55-TRAIL alone. These results suggest that additive induction of apoptosis was developed in the cells coinfected with ZD55-IL-24 and ZD55-TRAIL. No apoptosis was detected in normal cells infected with either of the viruses or their combination.
Antitumor effect of the combinational use of ZD55-IL-24 and ZD55-TRAIL in animal tumor model Owing to expression of TRAIL can be induced and enhanced by IL-24, the combined use of ZD55-IL-24 and ZD55-TRAIL should have synergistic effect for the treatment of cancer. ZD55-gene, is not only deleted of E1B 55-kDa gene similar to ONYX-015, but also armed with foreign antitumor gene. ONYX-015 was used as control. Consequently, the tumor growth inhibition efficacy of the combined viral therapy was studied in vivo. Tumor model in nude mice bearing human colorectal SW620 cancer was established by implantation of SW620 cells in the right flank of the animal. When the tumors grew to 100-150 mm 3 , they were treated with PBS, ONYX-015, ZD55-TRAIL, ZD55-IL-24 or the combination use of the last two by intratumoral injection every day for a total virus dosage of 2 Â 10 9 PFU. The results of this experiment are shown in Figure 3a . The tumor growth was inhibited in either group treated with viruses compared to negative control group treated with PBS. Interestingly, combined treatment of ZD55-IL-24-and ZD55-TRAIL led to complete elimination of tumor masses in all treated animals.
As shown in Figure 3b , long-term survival rate was observed in combination-treated group through KaplanMeier survival analysis (100%), whereas the rate of ZD55-IL-24 and ZD55-TRAIL-treated mice was 75 and 62.5%. These results demonstrate the promising antitumor effect of combined treatment of ZD55-IL-24 and ZD55-TRAIL in vivo.
Identification of the antitumor effect in vivo by immunohistochemistry and TUNEL Seven days after the first injection, tumor specimens were collected to perform immunohistochemistry and TUNEL staining. The results of immunohistochemistry and TUNEL are shown, respectively, in Figure 4a 
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The expression of IL-24 and TRAIL could be detected simultaneously in the same tumor cells treated with ZD55-IL-24 and ZD55-TRAIL. As shown in Figure 4b , the combined treatment dramatically induced tumor apoptosis, whereas tumors from animals treated with ZD55-IL-24 or ZD55-TRAIL alone resulted in less tumor cell apoptosis. These results suggested that the combined therapy is most effective in vivo when compared with either ZD55-IL-24 or ZD55-TRAIL therapy alone.
Caspase activation and release of cytochrome c by ZD55-TRAIL, ZD55-IL-24 or their combined treatment To determine the mechanism responsible for the synergistic inhibitory effects of the viruses, ZD55-IL-24 and ZD55-TRAIL, activation of caspases and release of These results suggest that the combined use of ZD55-IL-24 and ZD55-TRAIL can induce the caspase cascade activation in a synergistic manner. The release of cytochrome c from mitochondria was also observed, which then interacts with Apaf-1, causing self-cleavage and activation of caspase-9. Previous studies demonstrated that Ad-IL-24 could induce changes in the levels and ratio of proapoptotic to antiapoptotic proteins in several tumor cell lines, including breast and pancreatic carcinomas, melanomas and malignant gliomas. These changes may be the important mediators in mda-7/IL-24-induced apoptosis. To test if the changes of antiapoptotic and proapoptotic proteins contribute to the apoptosis in the colorectal cancer cells infected with ZD55-IL-24 and ZD55-TRAIL, the levels of proteins were determined by Western blotting. Bcl-2 protein protects cells from undergoing apoptosis, whereas Bax stimulates apoptosis in specific target cells. As shown in Figure 5b , upregulation of Bax was evident in the cells infected with any of the studied viruses and the expression level of bcl-2 was almost the same following infection of these viruses. Figure 5 Activation of the caspases and release of cytochrome c after infection of ZD55-IL-24 and ZD55-TRAIL. (a) SW620 cells were infected with ZD55-IL-24, ZD55-TRAIL or ZD55-IL-24 and ZD55-TRAIL, and PBS treatment was used as a negative control. After treatment for 48 h, cell extracts were subjected to Western blot analysis for activation of the caspase 3, caspase 8 and Parp. Changes in band densities were estimated using Image-Pro Plus analysis software. (b) The release of Cyto C, Bax and Bcl-2 protein levels was also detected. Actin was used as a loading control. Densitometric analysis was carried out using Image-Pro Plus analysis software.
Blockade of caspase activation inhibits ZD55-TRAILand ZD55-IL-24-induced apoptosis As the activation of apoptosis is induced by the expression of IL-24 or TRAIL, the role of caspases was studied in the presence of a broad-range caspase inhibitor Z-VAD.fmk containing culture medium. Figure 6a shows the percentage of cell death measured by MTT after treatment with ZD55-IL-24, ZD55-TRAIL or their combination with and without Z-VAD.fmk. The caspase inhibitor is capable of partly inhibiting cell growth after treatment with different oncolytic adenoviruses. In view of the results obtained by the use of Z-VAD.fmk, the inhibitory effect to ZD55-IL-24-infected cells was much less than ZD55-TRAIL-infected cells. These results indicate that ZD55-TRAIL is more dependent on the usual caspase cascade than ZD55-IL-24 to induce cell death (Figure 6a ). In order to confirm the observed effects, the percentage of cells undergoing apoptosis was measured by flow cytometry (Figure 6b ). The apoptosis was largely inhibited by Z-VAD.fmk following transduction with ZD55-TRAIL compared with ZD55-IL-24. Apoptosis induced by ZD55-IL-24 was only partly inhibited by Z-VAD.fmk. But for the ZD55-TRAIL-infected cells, the apoptosis was almost completely inhibited after the caspase inhibitor Z-VAD.fmk was added. These data 
Discussion
Mda-7/IL-24 is a tumor suppressor gene first identified by subtraction hybridization of a melanoma cell line induced to terminally differentiate with interferon-b and mezerein. 31 Ad-IL-24 showed potent activity of growth suppression and apoptosis induction to many different tumor types, including melanoma, glioblastoma multilforme, osteosarcoma and carcinomas of breast, colon, lung, cervix, kidney and prostate. Furthermore, the special point was that no cytotoxicity mediated by IL-24 in a variety of normal tissue cells was found. 32, 33 In addition to the feature of selective apoptosis induction, additional antitumor properties of mda-7/IL-24 were also observed. These include inhibition of tumor cell invasion and migration, 34, 35 potent antiangiogenic effects, 36, 37 immune stimulatory activity 38, 39 and direct bystander cytotoxicity. 40 In recent studies, a phase I clinical trial was initiated using intratumoral injections of nonreplicating adenovirus vector harboring the mda-7/IL-24 gene (Admda-7; INGN 241). INGN 241 can induce apoptosis in a large part of tumor volume following a single intratumoral injection. But significant response can only be seen with repeat injections. Sustained expression of IL-24 can be obtained by improving delivering vehicles. An oncolytic adenovector, replicating virus, will provide more efficient delivery of mda-7/IL-24 and is likely to be associated with greater clinical effect. In this report, an oncolytic virus ZD55-IL-24, which has the selective replication ability, was used and our study has demonstrated that its cytopathic and antitumor activity was much more evident than that of Ad-IL-24.
Some studies reported that significant antitumor effect could be obtained by combined use of different antitumor genes with different properties. The combination of Ad-IL-2 and Ad-IL-12, 41 Ad-Bax and Ad-TRAIL, 30 Ad-tk and immunotherapy or antiangiogenic therapy has been studied. [42] [43] [44] [45] All the above experiments have got good antitumor effect, but experimental data about complete eradication of the tumor masses in all studied animals have not been published. In this study, we constructed tumor selective replicating adenoviral vector ZD55 that can replicate and induce CPE similar to ONYX-015 and two therapeutic genes IL-24 and TRAIL were incorporated into this vector separately. At the same time, ZD55-IL-24 and ZD55-TRAIL were used in combination for the treatment of colorectal cancer as they have synergistic effect. Our results showed that treatment with ZD55-IL-24 or ZD55-TRAIL alone could suppress tumor growth and prolong survival of the animals. However, the strong antitumor activity and further prolonged survival were only observed in the case of combined use of ZD55-IL-24 and ZD55-TRAIL. All the tumor masses were completely eradicated in all mice by the combined treatment. No toxicity had been seen in any of the evaluated therapies.
TRAIL is a member of the TNF family and has been previously demonstrated to induce apoptosis in cancer cells both in vitro and in vivo. 46 It was reported that Ad-IL-24 could upregulate the expression of TRAIL in both H1299 and A549 tumor cells but not in normal cells. 8 But no further evidence was available. In this article, we reported that ZD55-IL-24 could obviously induce TRAIL expression as shown in Figure 2a , and both ZD55-IL-24 and its combination with ZD55-TRAIL could induce expression of the apoptotic death receptor DR4. The antiangiogenic effect of IL-24 was also reported and endothelial cell differentiation was inhibited by the expression of IL-24. This may also contribute to the complete eradication of the tumor in animal experimental models. These results provide further impetus for the combined use of ZD55-IL-24 and ZD55-TRAIL to target cancer cells to induce apoptosis, including those tumors that may display resistance to either agent used alone.
Studies from literature have demonstrated that treatment with a pancaspase inhibitor, Z-VAD.fmk, inhibits apoptosis induced by Ad-TRAIL in a variety of cancer cell types. 47 Similar results have been obtained in our experiment and the apoptosis induced by ZD55-TRAIL was almost completely inhibited. However, the apoptosis induced by ZD55-IL-24 was less inhibited than that induced by ZD55-TRAIL. Application of DMSO, the carrier of Z-VAD.fmk, had no effect on apoptosis. The results showed that the defect in the caspase cascade is not sufficient to block cell death mediated by ZD55-IL-24. The difference between IL-24 gene and other currently identified tumor suppressor genes is its diverse mechanisms underlying apoptosis-inducing properties. Therefore, this result indicated that ZD55-IL-24 was able to induce apoptosis in a series of colorectal cancer cell lines with a variety of mutated apoptotic signaling pathways.
In conclusion, this study is the first to show that the combined use of ZD55-IL-24 and ZD55-TRAIL synergistically induces growth suppression and apoptosis in human colorectal cancer cell lines in vitro and inhibits human colon tumor growth in vivo. The apoptosis signaling pathways were also studied. Our study points the way for development of novel strategies for cancer gene therapy that involve the combined delivery of two tumor suppressor genes that can synergistically induce apoptosis in cancer cells with a defined genotype.
Abbreviations CPE, cytopathic effect; DR4, death receptor 4; Mda-7, melanoma differentiation associated gene-7; MOI, multiplicity of infection; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly(ADPribose) polymerase; TUNEL, TdT-mediated dUTP-biotin nick end labeling; ZD55, recombinant adenovirus with E1B 55 KDa gene deletion.
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